SCHEMBL2011968

SCHEMBL2011968

CC(C)(C)OC(=O)NCC(O)c1cccc(O)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 3/20 0.56
RAB9A P51151 3/20 0.56
ADRB2 P07550 1/20 0.56
ADRB1 P08588 1/20 0.56
HTR1A P08908 1/20 0.56
ADRA2A P08913 1/20 0.56
ADRB3 P13945 1/20 0.56
TSHR P16473 1/20 0.56
ADRA2B P18089 1/20 0.56
ADRA2C P18825 1/20 0.56
NFKB1 P19838 1/20 0.56
DRD1 P21728 1/20 0.56
HTR7 P34969 1/20 0.56
ADRA1A P35348 1/20 0.56
ADRA1B P35368 1/20 0.56
DRD3 P35462 1/20 0.56
SLC6A3 Q01959 1/20 0.56
LMNA P02545 4/20 0.55
KDM4E B2RXH2 1/20 0.55
GAA P10253 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11243509 0.88 LMNA (0.53) HIF1ARAB9AADRB2ADRB1HTR1A
SCHEMBL2204205 0.87 NQO2 (0.51) HIF1ARAB9AADRB2ADRB1HTR1A
SCHEMBL16031480 0.87 NQO2 (0.51) HIF1ARAB9AADRB2ADRB1HTR1A
SCHEMBL12321338 0.86 BCAT2 (0.43) RAB9AADRB2ADRB1ADRB3LMNA
SCHEMBL5672990 0.85 AAK1 (0.47) RAB9ALMNASYKNPC1SMN1; SMN2
SCHEMBL31724249 0.85 AAK1 (0.47) RAB9ALMNASYKNPC1SMN1; SMN2
SCHEMBL26603876 0.85 AAK1 (0.47) RAB9ALMNASYKNPC1SMN1; SMN2
SCHEMBL10319930 0.85 CTSL (0.47) ADRB2ADRB1ADRB3ADRA1AADRA1B
SCHEMBL4597974 0.85 CTSL (0.47) ADRB2ADRB1ADRB3ADRA1AADRA1B
SCHEMBL16690784 0.85 CTSL (0.47) ADRB2ADRB1ADRB3ADRA1AADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 US disclosed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 US disclosed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 US disclosed
EP-1677783-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE Nicholas Piramal India Limited (IN) 2006-07-12 EP disclosed
WO-2005035495-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE NICHOLAS PIRAMAL INDIA LIMITED (IN) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE FGB, F13B, F2 HIF1A 3365/4885RAB9A 2816/4885ADRB2 636/4885
US-20070021489-A1 Fibrinogen receptor antagonists and their use FGB, F13B, F2 HIF1A 3365/4885RAB9A 2816/4885ADRB2 636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.